


**Diagnostics & Precision Medicine Summit 2016**  
June 21, 2016

Company Presentation/Poster Application

Company Name	Advaxis, Inc.
Life Sciences Sector	<input type="checkbox"/> Diagnostics <input checked="" type="checkbox"/> Biotech <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other (specify):
Commercial Focus/Therapeutic Area	Cancer Immunotherapy
Company Description (max 50 words)	<i>Please attach</i>
Company Development/Commercial Stage	Clinical-stage biotechnology company
Product Name (if applicable)	ADX5-NEO
Product Description – Include value and advancements that the product brings to Precision Medicine (max 100 words)	<i>Please attach</i>
Funding Status	
Presentation/Poster Objectives	<input checked="" type="checkbox"/> Partnering <input checked="" type="checkbox"/> Funding <input type="checkbox"/> Other (specify):
Contact Name/Title	Daniel O'Connor, President & CEO
Contact Information <i>See Attached, form not working</i>	Email: <u>See Attached</u> Phone: Address:

***Thank You to Our Sponsors***



**Advaxis, Inc. Company Presentation/Poster Application**

**Diagnostics & Precision Medicine Summit 2016**

**June 21, 2016**

**Company Description (Max 50 Words)**

Advaxis is a clinical-stage biotechnology company developing cancer immunotherapies that enlist the body's own immune system to fight cancer. Advaxis' *Lm* Technology™ (live attenuated *Listeria monocytogenes*) generates cancer-fighting T cells which are directed against cancer antigens and alters the tumor microenvironment, making it susceptible to immunologic attack.

**Product Description (Max 100 Words)**

The ADXS-NEO platform aims to activate a patient's immune system to respond against the unique mutations, or neo-epitopes, contained in each individual patient's tumor. This strategy, using massive parallel sequencing, eliminates the need for "predictive" algorithms and enables the development of truly individualized immunotherapies that can be manufactured in a manner that is cost-effective and timely for patients.

Because the immune response is activated only against the mutated neo-epitopes, there is little-to-no systemic blockade of tolerance or off-target toxicity. If successful, ADXS-NEO could potentially bring about a next generation of truly individualized cancer immunotherapies.

**Contact Information:**

Daniel O'Connor, President & CEO

Email: [odonnor@advaxis.com](mailto:odonnor@advaxis.com)

Phone: 609-452-9813

Address: 305 College Road, East, Princeton, NJ